(+)-Thalidomide
SIGMA/T151 - ≥98% (HPLC), powder
Synonym: R-
CAS Number: 2614-06-4
Empirical Formula (Hill Notation): C13H10N2O4
Molecular Weight: 258.23
MDL Number: MFCD00210220
Linear Formula: C13H10N2O4
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI | 1S/C13H10N2O4/c16-10-6-5- |
| InChI key | UEJJHQNACJXSKW-SECBINFHSA |
| originator | Celgene |
| SMILES string | O=C1CC[C@@H](N2C(=O)c3ccc |
| solubility | DMSO: 15 mg/mL, clear |
| storage temp. | room temp |
| Application: | Thalidomide has been used to study its teratogenic effects in chicken embryos and human embryonic cells. This study reported that thalidomide causes limb defects by stabilizing PTEN, inhibiting the expression of Akt and activating caspase-dependent apoptosis. Thalidomide has also been used for studying glutathione mediated teratogenic resistance in mouse embryos. |
| Biochem/physiol Actions: | (-)-Thalidomide selectively inhibits biosynthesis of tumor necrosis factor α (TNF-α). (R)-Thalidomide is called "safe enantiomer", but it can be converted in the body to (S)-isomer. |
| Features and Benefits: | This compound was developed by Celgene  . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 10, 100 mg in glass bottle |
| Preparation Note: | Thalidomide is soluble in DMSO at a concentration that is greater than or equal to 20 mg/ml. It is insoluble in ethanol and water. |
| Symbol |   GHS07,GHS08 |
| Signal word | Danger |
| Hazard statements | H302 - H360 |
| Precautionary statements | P201 - P301 + P312 + P330 - P308 + P313 |
| Hazard Codes | T |
| Risk Statements | 61-22 |
| Safety Statements | 53-36/37/39-45 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | room temp |
| UNSPSC | 12352200 |